Standard BioTools Inc. reports developments in life-science research tools built around proprietary mass cytometry and microfluidics technologies. The company sells instruments, consumables and services for genomics, single-cell proteomics and spatial proteomics, including platforms such as Biomark X9, CyTOF XT and Hyperion systems used in research workflows.
Recurring news includes operating and financial results, capital-structure updates, shareholder voting and governance matters, portfolio actions following the completed sale of SomaLogic assets, and collaborations that expand imaging mass cytometry and multi-omic research applications. Company updates also describe translational and clinical research use cases in oncology, immunology and immunotherapy, with products positioned for research use rather than diagnostic procedures.
Standard BioTools (NASDAQ: LAB) has entered into a definitive agreement to sell its Microfluidics business to healthcare investment firm ARCHIMED.
The transaction is expected to close in approximately 30 days, subject to customary closing conditions. Until closing, the Microfluidics business will continue to operate as part of Standard BioTools. Chief Executive Officer Michael Egholm said the company believes the business will continue to grow and innovate under new ownership.
Standard BioTools (LAB) signed a definitive agreement to sell its Mass Cytometry business to Element Biosystems for $5.5 million in cash. Element is an acquisition vehicle formed by GMT Venture Partners. Payment is due at closing, subject to customary adjustments. Standard BioTools and Multiplex Bio mutually terminated their earlier purchase agreement after the board determined that Element's transaction was a superior proposal.
The replacement agreement removes the obligation to provide a $10 million working capital loan. Standard BioTools expects approximately $15 million more net cash to count toward the final exchange ratio for its Treeline Biosciences merger, compared with the Multiplex Bio transaction, after related termination and transaction fees. The company expects both transactions to close by the end of 2026, substantially concurrently, subject to Standard BioTools stockholder approval and customary closing conditions.
Standard BioTools (NASDAQ: LAB) reported second quarter 2026 revenue of $20.1 million, down 7.6% year-over-year, with consumables, instruments, and services all declining. GAAP gross margin improved to 52.4% and non-GAAP gross margin to 56.3%, driven by productivity gains and lower warranty costs.
GAAP operating expenses were $35.9 million, including $14.7 million of transaction costs and $2.8 million of restructuring charges. Non-GAAP operating expenses fell 50% to $13.8 million. Net loss from continuing operations was $21.5 million, while adjusted EBITDA loss improved 84% to $2.5 million. Cash, cash equivalents and investments totaled $541.1 million at June 30, 2026.
The company highlighted progress toward its planned merger with Treeline Biosciences, an agreement to divest its Mass Cytometry business, and a $30 million early buyout of contingent payments by Illumina. Standard BioTools withdrew its full-year 2026 revenue outlook due to the pending merger.
Standard BioTools (NASDAQ: LAB) announced several developments tied to its pending merger with Treeline Biosciences. The company agreed to sell its Mass Cytometry business, including the CyTOF and Hyperion product lines, to Multiplex Bio, a new entity led by advanced imaging industry veterans. The transaction is valued at up to $10 million, consisting of a seller’s note and a potential milestone payment, and Standard BioTools will provide a working capital loan of up to $10 million at closing. Separately, Standard BioTools received approximately $30 million from Illumina in a negotiated buyout of the 2026 earnout and all accrued and unpaid royalties related to Illumina’s prior acquisition of the SomaLogic business. This cash will be included in Standard BioTools’ pro forma net cash position used in the Treeline exchange ratio. The company also reported early termination of the Hart-Scott-Rodino waiting period and expects the Treeline merger to close by year-end 2026, subject to stockholder approval and customary conditions.
Standard BioTools (NASDAQ: LAB) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. market close. The company develops standardized next-generation life science tools for biomedical research, provided for research use only and not for diagnostic procedures.
Standard BioTools (NASDAQ: LAB) filed a Form S-4 registration statement with the SEC for its previously announced all-stock merger with Treeline Biosciences. Closing is expected in the second half of 2026, after which the combined company will be named Treeline Biosciences Holdings and trade on Nasdaq as TRLN.
The filing highlights Treeline’s discovery organization and pipeline, including TLN-121, TLN-254, TLN-372 and TLN-499. Initial Phase 1 monotherapy data for TLN-121 in relapsed/refractory lymphomas showed an 84% overall response rate and 32% complete response rate (19 patients), with no dose-limiting toxicities and mostly Grade 1 adverse events. According to Standard BioTools, interim data readouts for TLN-121 and TLN-372 are planned for 2027.
The combined company is expected to have over $900 million in pro-forma cash at closing, which is expected to fund operations and Treeline’s development pipeline into 2029. Treeline has previously raised about $1.2 billion. Treeline also added industry leader Sue Desmond-Hellmann to its Board of Directors.
Standard BioTools (NASDAQ: LAB) and Treeline Biosciences agreed to an all-stock merger, creating a publicly traded company named Treeline Biosciences expected to list on Nasdaq as TRLN in 2H 2026.
The combined company should have over $900 million pro-forma cash, adding about $450 million from Standard BioTools, funding operations into 2029 and advancing Treeline’s pipeline of three Phase 1 programs plus multiple planned clinical entrants through 2028.
Pre-merger Standard BioTools holders are expected to own about 16% and receive a CVR tied to potential proceeds from legacy Mass Cytometry, Microfluidics and Illumina-related earnouts.
Standard BioTools (NASDAQ: LAB) reported first quarter 2026 continuing‑operations revenue of $21.1 million, up 5% year‑over‑year, with gross margin ~53.5% and non‑GAAP gross margin ~57.7%. Adjusted EBITDA was a loss of $3.1 million (78% improvement YoY). Cash and investments were $523.6 million at quarter end, and the company reiterated 2026 revenue guidance of $80–$85 million.
Operating expenses fell 37% to $23.8 million, including $3.1 million of restructuring charges; consumables revenue grew 35% to $11.0 million.
Standard BioTools (NASDAQ: LAB) will report its first quarter 2026 financial results on May 5, 2026, to be released after the U.S. market close.
Investors can expect a post-close release and likely an accompanying conference call or investor materials referenced by the company.
Standard BioTools (NASDAQ: LAB) reported fourth-quarter continuing-operations revenue of $23.8M and full-year 2025 revenue of $85.3M. The company said it fully operationalized over $40M of annualized cost savings, exited the year with meaningfully lower run-rate expenses, and held approximately $550M in cash and investments following the SomaLogic closing.
Gross margin improved to 49.9% for 2025; net loss narrowed to $58.8M. Management expects 2026 revenue of $80M–$85M and noted about $1B in US NOL carryforwards.